Why PGD₂ has different functions from PGE₂

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Prostaglandin (PG) D2 and PGE2 are positional isomers with sometimes opposing physiological functions, notably in cancer development.
• DP receptors are considered duplicated copies of EP2 receptors, leading to cross-reactivity between PGD2, PGE2, and these receptors.
• These prostanoids may function as biased agonists, selectively activating specific signaling pathways for each receptor.

Purpose of the Study:

• To propose a hypothesis explaining the opposing effects of PGD2 and PGE2 on cancer development.
• To investigate the roles of receptor evolution, mutations, and biased activities in mediating these opposing effects.
• To understand the molecular mechanisms underlying prostaglandin signaling in cancer.

Main Methods:

• Review of existing literature on prostaglandin receptors and their signaling pathways.
• Analysis of evolutionary data regarding DP and EP2 receptors, including mutation and variation frequencies.
• Hypothesis generation based on comparative analysis of receptor evolution and prostanoid-receptor interactions.

Main Results:

• DP receptors exhibit more mutations and variations globally compared to EP2 receptors, suggesting a rapid evolutionary stage.
• Prostaglandin E2 may act as a biased agonist for DP receptors, contributing to opposing physiological functions.
• The evolution of DP receptors and biased signaling by PGE2 are hypothesized to explain the differential effects on cancer.

Conclusions:

• The opposing effects of PGD2 and PGE2 in cancer may be linked to the evolutionary dynamics of DP receptors.
• Biased agonism of PGE2 at DP receptors, potentially arising during receptor evolution, could mediate these opposing effects.
• Further research is needed to elucidate the precise mechanisms of biased signaling and its implications for cancer therapy.